临床用药|IgA 肾病？靶向治疗了解一下！，病因层面治疗( 三 )
12.MatousovicK,NovakJ,YanagiharaT,etal.IgA-containingimmunecomplexesintheurineofIgAnephropathypatients.NephrolDialTransplant.2006;21:2478-84.
13.AllenAC,BaileyEM,BrenchleyPE,etal.MesangialIgA1inIgAnephropathyexhibitsaberrantO-glycosylation:observationsinthreepatients.KidneyInt.2001;60:969-73.
14.InoueT,SugiyamaH,HikiY,etal.DifferentialexpressionofglycogenesintonsillarBlymphocytesinassociationwithproteinuriaandrenaldysfunctioninIgAnephropathy.ClinImmunol.2010;136:447-55.
15.WyattRJ,JulianBA.IgAnephropathy.NEnglJMed.2013;25(368):2402-14.
16.KerrMA.ThestructureandfunctionofhumanIgA.BiochemJ.1990;271:285-296.
17.TarelliE,SmithAC,HendryBM,etal.HumanserumIgA1issubstitutedwithuptosixO-glycansasshownbymatrixassistedlaserdesorptionionizationtime-of-flightmassspectrometry.CarbohydrRes.2004;339:2329-35.
18.GomesMM,SuzukiH,BrooksMT,etal.Recognitionofgalactose-deficientO-glycansinthehingeregionofIgA1byN-acetylgalactosamine-specificsnaillectins:acomparativebindingstudy.Biochemistry.2010;49:5671-82.
19.BoydJK,CheungCK,MolyneuxK,etal.AnupdateonthepathogenesisandtreatmentofIgAnephropathy.KidneyInt.2012;81:833.
20.BarrattJ,FeehallyJ.PrimaryIgAnephropathy:newinsightsintopathogenesis.SeminNephrol.2011;31:349.
21.ZhangYM,ZhangH.InsightsintotheRoleofMucosalImmunityinIgANephropathy.ClinJAmSocNephrol.2018;13:1584-6.
22.WattsP,SmithA.TARGITtechnology:coatedstarchcapsulesforsite-specificdrugdeliveryintothelowergastrointestinaltract.ExpertOpinDrugDeliv.2005;2:159–67.
23.Edsb?ckerS,WollmerP,Nilsson?,etal.Pharmacokineticsandgastrointestinaltransitofbudesonidecontrolledilealrelease(CIR)capsules.Gastroenterology.1993;104:A695.
24.SmithAC,MolyneuxK,FeehallyJ,etal.O-glycosylationofserumIgA1antibodiesagainstmucosalandsystemicantigensinIgAnephropathy.JAmSocNephrol.2006;17:3520–8.
25.FellstromBC,BarrattJ,CookH,etal.Targeted-releasebudesonideversusplaceboinpatientswithIgAnephropathy(NEFIGAN):adouble-blind,randomised,placebo-controlledphase2btrial.Lancet.2017;389:2117–127.
26.LvJC,ZhangH,WongMG,etal.EffectofOralMethylprednisoloneonClinicalOutcomesinPatientsWithIgANephropathy:TheTESTINGRandomizedClinicalTrial.JAMA.2017;318(5):432-42.
27.RauenT,EitnerF,FitznerC,etal.IntensiveSupportiveCareplusImmunosuppressioninIgANephropathy.NEnglJMed.2015;373(23):2225-36.
【临床用药|IgA 肾病？靶向治疗了解一下！，病因层面治疗】28.CalliditasTherapeuticsAB.EfficacyandsafetyofNefeconinpatientswithprimaryIgA(immunoglobulinA)nephropathy(Nefigard).2019.Availableat:https://clinicaltrials.gov/ct2/show/NCT03643965.
推荐阅读
- 治疗干咳的9种常用药，建议收藏
- 降压药如何联合用药？建议通看5遍
- 科学用药解便秘，生活习惯更重要
- 手把手教你学舌诊 四种常见舌象用药一看就会
- 山东省戴庄医院召开LY03010临床试验项目启动会
- 带状疱疹的西医用药治疗，强烈建议收藏
- 让处方用药不再难！全省首个电子处方流转监管服务平台试运行
- 国医大师柴嵩岩妇科临床经验系列丛书发布
- 干货 | 玉屏风散的18种联合用药
- 湖南省医学会精神病学专业委员会基层临床技能提升培训班（怀化站）圆满结束